Nonetheless, considering that clinical testing of NaPi2b targeting antibody-drug conjugate strategies has been halted due to grade ≥3 adverse events in ovarian cancer [49], our preliminary findings lay the foundation for NaPi2b targeting CAR-T strategies for antigen-specific superior cytotoxicity and bystander killing of antigen-negative ovarian tumor cells. Here, SLC34A2 is linked to ovarian carcinoma.